Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 111 to 120 of 171 total matches.

Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
concentrations and renal function BCRP = breast cancer resistance protein; DAA = direct-acting antiviral drug ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175   doi:10.58347/tml.2024.1714f |  Show IntroductionHide Introduction

Phexxi - A Nonhormonal Contraceptive Gel

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
Decreased risk of ovarian and endometrial cancer, PID, and dysmenorrhea; cycle control Increased risk ...
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):129-32 |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
, strong CYP2C8 inhibitors or inducers, or breast cancer resistance protein (BCRP) inhibitors. How ...
The FDA has approved ozanimod (Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). It is the third oral S1P receptor modulator to be approved in the US for treatment of relapsing forms of MS; siponimod (Mayzent) is also indicated for use in adults, and fingolimod (Gilenya) is approved for use in patients ≥10 years old.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):132-4 |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
for treatment of severe chronic cancer pain. DOSAGE — Opioid dosage requirements vary widely among patients ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction

Avapritinib (Ayvakit) for GIST

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
Options Oncol 2020; 21:55. 4. Regorafenib (Stivarga) for metastatic colon cancer and GIST. Med Lett ...
The FDA has approved the oral tyrosine kinase inhibitor avapritinib (Ayvakit – Blueprint Medicines) for treatment of unresectable or metastatic gastrointestinal stromal tumors (GISTs) harboring a platelet-derived growth factor receptor alpha (PDGFRA) D842V or other PDGFRA exon 18 mutation. Avapritinib is the first drug to be approved for this indication in the US.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):23-4 |  Show IntroductionHide Introduction

Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
-glycoprotein (P-gp) and is a moderate inhibitor of CYP2C8 and breast cancer resistance protein (BCRP ...
The Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca – Lilly) has received accelerated approval from the FDA for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who received ≥2 prior lines of systemic therapy, including a BTK inhibitor. Accelerated approval was based on the response rate. The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are also approved for treatment of MCL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e35-6   doi:10.58347/tml.2023.1670f |  Show IntroductionHide Introduction

Belzutifan (Welireg) for Advanced Renal Cell Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024  (Issue 1701)
. www.fdbhealth.com/drug-pricing-policy. Afinitor everolimus renal cell cancer Welireg belzutifan ...
Belzutifan (Welireg – Merck), a first-in-class hypoxia-inducible factor inhibitor, has been approved by the FDA for treatment of advanced renal cell carcinoma (RCC) in adults who received prior treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). Belzutifan was previously approved for use in patients with von Hippel-Lindau disease.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e75-6   doi:10.58347/tml.2024.1701g |  Show IntroductionHide Introduction

Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021  (Issue 1634)
. www.fdbhealth.com/drug-pricing-policy. 2. Also available in various strengths for treatment of prostate cancer. 3 ...
Fensolvi (Tolmar), a long-acting subcutaneous formulation of the gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate, has been approved by the FDA for treatment of central precocious puberty (CPP) in children ≥2 years old. It is the first formulation of the drug to be approved for SC administration once every 6 months. IM formulations of leuprolide acetate, which are given once monthly or every 3 months, and the GnRH agonists histrelin acetate (Supprelin LA) and triptorelin (Triptodur) have been available for years for treatment of CPP.
Med Lett Drugs Ther. 2021 Sep 23;63(1634):e1-2 |  Show IntroductionHide Introduction

A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
and proliferation and secretion of inflammatory cytokines, which leads to T-cell-mediated destruction of cancer ...
The FDA recently approved axicabtagene ciloleucel (Yescarta – Kite), a CD19-directed genetically modified cellular product, for treatment of large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line treatment. It was previously approved for treatment of relapsed or refractory B-cell lymphoma after ≥2 lines of systemic therapy and for treatment of relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells,...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e194-5 |  Show IntroductionHide Introduction

In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
of inflammatory cytokines, which leads to T-cell-mediated destruction of cancer cells. CLINICAL STUDIES — FDA ...
The FDA has approved lisocabtagene maraleucel (Breyanzi – BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, or follicular lymphoma grade 3B who have disease refractory to first-line chemoimmunotherapy, relapsed within 12 months of or after first-line chemoimmunotherapy, are not eligible for hematopoietic stem cell transplantation due to comorbidities or age, or have relapsed or refractory disease after ≥2 lines of...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e104-5   doi:10.58347/tml.2023.1679f |  Show IntroductionHide Introduction